Watimar, Rachel .
HRN: 12-50-49 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
05/20/2024
CEFUROXIME 1.5GM (VIAL)
05/20/2024
05/21/2024
IV
1.5gm
Q8 X 3 Doses
S/P NSVD (RHU Delivery) With 2nd Deg And Repair; Inc WBC 29.2
Waiting Final Action
Indication: Empiric Type of Infection: Reproductive Tract Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes